| VCP — Valosin Containing Protein | |
|---|---|
| Symbol | VCP |
| Full Name | Valosin Containing Protein |
| Chromosome | 9p13.3 |
| NCBI Gene | 7415 |
| Ensembl | ENSG00000165288 |
| OMIM | 601023 |
| UniProt | P55072 |
| Diseases | ALS, FTD, Inclusion Body Myopathy |
| Expression | Ubiquitous (high in brain, muscle) |
| Key Mutations | |
| P137L, R155H, R155P, R155C, D592N, A439T | |
VCP (Valosin Containing Protein), also known as p97, is a highly conserved AAA+ ATPase essential for protein quality control, DNA repair, and cellular homeostasis. VCP is uniquely positioned at the intersection of multiple degradation pathways, including the ubiquitin-proteasome system, autophagy, and ER-associated degradation (ERAD). Mutations in VCP cause a spectrum of degenerative diseases including inclusion body myopathy with early-onset Paget disease of bone and frontotemporal dementia (IBMPFD), amyotrophic lateral sclerosis (ALS), and FTD. VCP dysfunction leads to impaired protein clearance, mitochondrial dysfunction, and autophagic stress—all central features of neurodegeneration.
VCP (Valosin Containing Protein) is a AAA+ ATPase encoded by the VCP gene on chromosome 9p13.3. VCP functions as a molecular segregase, using ATP hydrolysis to extract ubiquitinated proteins from membranes, chromatin, and protein complexes. VCP mutations cause inclusion body myopathy with early-onset Paget disease of bone and frontotemporal dementia (IBMPFD), as well as ALS/FTD. The protein is essential for protein quality control, mitophagy, ERAD, and DNA repair. VCP is ubiquitously expressed with particularly high levels in neurons and muscle cells, explaining the tissue-specific degeneration seen in VCP-linked diseases.
VCP is a 806 amino acid protein (approximately 97 kDa) with a modular domain architecture:
N-terminal domain (N-domain): Binds cofactors and ubiquitinated substrates. Contains the binding sites for various VCP adaptor proteins including Ufd1, Npl4, and p47.
D1 ATPase domain (residues 200-460): The first ATPase domain responsible for ATP binding and hydrolysis. Forms a hexameric ring with other VCP subunits.
D2 ATPase domain (residues 500-760): The second ATPase domain providing additional ATPase activity essential for substrate processing.
C-terminal tail: Contains regulatory sequences and interaction motifs.
VCP serves as a central hub for protein homeostasis:
ER-associated degradation (ERAD): VCP extracts misfolded proteins from the endoplasmic reticulum for proteasomal degradation. This function is essential for maintaining ER homeostasis and preventing accumulation of toxic protein species.
Retrotranslocation: VCP power the retrotranslocation of ubiquitinated substrates from the ER lumen or membrane to the cytoscom for proteasomal clearance.
Mitophagy: VCP is essential for Parkin-dependent mitophagy, facilitating the removal of damaged mitochondria. VCP mutations impair mitophagy, leading to accumulation of dysfunctional mitochondria.
Chromatin remodeling: VCP participates in DNA repair and transcription regulation by extracting proteins from chromatin.
Aggresome/autophagosome formation: VCP helps form and clear aggresomes and autophagosomes, particularly under proteotoxic stress conditions.
VCP mutations cause approximately 1-2% of familial ALS cases and are a common cause of IBMPFD. The pathogenic mechanisms include:
Impaired protein clearance: VCP mutations disrupt the extraction of ubiquitinated substrates from membranes and complexes, leading to accumulation of misfolded proteins. This includes TDP-43, a key aggregating protein in ALS/FTD.
Mitochondrial dysfunction: VCP is critical for mitophagy. Mutations impair clearance of damaged mitochondria, leading to increased oxidative stress and bioenergetic failure.
Autophagic stress: VCP mutations cause accumulation of autophagic intermediates and impaired lysosomal clearance. This creates a bottleneck in the autophagy pathway.
DNA repair deficits: VCP participates in DNA double-strand break repair. Mutations may increase genomic instability in neurons.
Stress granule dynamics: VCP is recruited to stress granules under proteotoxic stress. Mutations alter stress granule composition and dynamics.
VCP mutations cause a characteristic inclusion body myopathy with early-onset Paget disease of bone. Muscle biopsies show rimmed vacuoles containing aggregated proteins, similar to the inclusions seen in neurodegenerative diseases.
Over 40 pathogenic VCP mutations have been identified:
Patients with VCP mutations present with a variable phenotype:
VCP is a promising therapeutic target:
VCP activity and autophagic markers in muscle and blood may serve as biomarkers for disease progression.
The study of Vcp — Valosin Containing Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.